Clinical Trial Update: VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

This document reports results from a Phase 2 clinical trial of Velcade (bortezomib) in patients with relapsed or refractory mantle cell lymphoma. The study stat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED